PSEN1 and Alzheimer disease: Taking the above disturbed lipid metabolites as the evaluation indices of therapeutic effect, the role of GBLE treatment on the plasma lipid fingerprint of AD was investigated through a comparison of APP/PS1+GBLE group vs.